GLPG
Galapagos N.V.
NASDAQ · Healthcare · Biotechnology · BE
$27.98
+1.71%Sep 1, 2026, 20:01 UTC
Lakefront Biotherapeutics NV repurchased 127,796 of its own shares between August 24 and August 28, 2026, under its buyback program announced on June 9, 2026, via a discretionary mandate to an independent intermediary.
Source:Aug 25, 2026, 20:01 UTC
Lakefront Biotherapeutics NV repurchased 117,471 of its own shares between August 17 and August 21, 2026, under its buyback program announced on June 9, 2026, via a discretionary mandate to an independent intermediary.
Source:Aug 24, 2026, 20:01 UTC
The U.S. FDA granted Orphan Drug Designation to gamgertamig for the treatment of pemphigus, as announced by Lakefront Biotherapeutics NV on 24 August 2026.
Source:Aug 24, 2026, 20:01 UTC
Lakefront Biotherapeutics NV received a transparency notification from Bank of America regarding a change in its shareholding.
Source:Aug 18, 2026, 20:01 UTC
Lakefront Biotherapeutics NV repurchased 107,871 of its own shares between August 10 and August 14, 2026, under its buyback program announced on June 9, 2026, for a total of €2,604,002.56.
Source:Jul 29, 2026, 00:00 UTC
Fortrea Holdings Inc. appointed David Smith as Interim Chief Financial Officer and principal financial officer, effective July 27, 2026.
Jun 23, 2026, 20:01 UTC
Lakefront Biotherapeutics NV repurchased 77,667 of its own shares between 15 June 2026 and 19 June 2026 under a buyback program announced on 9 June 2026.
Jun 9, 2026, 20:01 UTC
Lakefront Bio therapeutics NV initiated a €50 million stock repurchase program, with Morgan Stanley & Co International PLC as the counterparty.
Source: